Scribe Therapeutics disclosed plans to pursue an initial public offering after revealing details of its Nasdaq strategy in a Securities and Exchange Commission filing. The company, led by CEO Benjamin Oakes and co-founded with Jennifer Doudna, is developing genetic medicines for cardiometabolic disorders using an epigenetic silencing approach. Scribe’s lead candidate, STX-1150 for high cholesterol, entered the clinic in June 2026 and is designed as a single-dose therapy aimed at PCSK9 regulation. The company has also reported partnerships with Biogen, Sanofi and Prevail Medicines, spanning targets including ALS and NK-cell cancer programs. Backed by investors including Andreessen Horowitz, Avoro Ventures and OrbiMed, Scribe has raised $120 million to date and secured additional grant funding from the California Institute for Regenerative Medicine for atherosclerotic cardiovascular disease and acute pancreatitis programs.